ATP confers tumorigenic properties to dendritic cells by inducing amphiregulin secretion

Blood

Volumn 116, Issue 17, 2010, Pages 3219-3226

  Bles, Nathalie ^a   Di Pietrantonio, Larissa ^a   Boeynaems, Jean Marie ^a,b   Communi, Didier ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROSTAGLANDIN E2; PURINERGIC P2Y11 RECEPTOR; PURINERGIC RECEPTOR; URIDINE TRIPHOSPHATE;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DENDRITIC CELL; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; TUMOR VOLUME; UPREGULATION;

EID: 78049353527     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-265611     Document Type: Article

References (50)

1. Riboldi E, Musso T, Moroni E, et al. Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J Immunol. 2005;175(5):2788-2792.
2. Bles N, Horckmans M, Lefort A, et al. Gene expression profiling defines ATP as a key regulator of human dendritic cell functions. J Immunol. 2007;179(6):3550-3558.
3. Conejo-Garcia JR, Benencia F, Courreges MC, et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med. 2004;10(9):950-958.
4. Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother. 2007;56(6):761-770.
5. Hubbard NE, Lim D, Mukutmoni M, Cai A, Erickson KL. Expression and regulation of murine macrophage angiopoietin-2. Cell Immunol. 2005;234(2):102-109.
6. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101(7):2620-2627.
7. Marteau F, Gonzalez NS, Communi D, et al. Thrombospondin-1 and indoleamine 2,3-dioxygenase are major targets of extracellular ATP in human dendritic cells. Blood. 2005;106(12):3860-3866.
8. Shoyab M, McDonald VL, Bradley JG, Todaro GJ. Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci U S A. 1988;85(17):6528-6532.
9. Berasain C, Castillo J, Perugorria MJ, Prieto J, Avila MA. Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett. 2007;254(1):30-41.
10. Ma L, Serova M, Podgorniak MP, et al. Amphiregulin antisense RNA expression inhibits angiogenesis of human breast cancer in nude mice. Zhonghua Zhong Liu Za Zhi. 2005;27(9):521-523.
11. Ma L, Gauville C, Berthois Y, et al. Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line. Oncogene. 1999;18(47):6513-6520.
12. Desruisseau S, Palmari J, Giusti C, et al. Clinical relevance of amphiregulin and VEGF in primary breast cancers. Int J Cancer. 2004;111(5):733-740.
13. Kato M, Inazu T, Kawai Y, et al. Amphiregulin is a potent mitogen for the vascular smooth muscle cell line, A7r5. Biochem Biophys Res Commun. 2003;301(4):1109-1115.
14. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176(6):1693-1702.
15. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223(1):77-92.
16. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):1-11.
17. Shin HS, Lee HJ, Nishida M, et al. Betacellulin and amphiregulin induce upregulation of cyclin D1 and DNA synthesis activity through differential signaling pathways in vascular smooth muscle cells. Circ Res. 2003;93(4):302-310.
18. Inagawa H, Nishizawa T, Noguchi K, et al. Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system. Anticancer Res. 1997;17(3C):2153-2158.
19. Inagawa H, Nishizawa T, Takagi K, et al. Antitumor mechanism of intradermal administration of lipopolysaccharide. Anticancer Res. 1997;17(3C):1961-1964.
20. Gabrilovich D, Pisarev V. Tumor escape from immune response: mechanisms and targets of activity. Curr Drug Targets. 2003;4(7):525-536.
21. Whiteside TL. The role of immune cells in the tumor microenvironment. Cancer Treat Res. 2006;130(1):103-124.
22. Harmey JH, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol. 1998;5(3):271-278.
23. Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology. 2001;103(4):449-457.
24. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4(12):941-952.
25. Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood. 1998;92(12):4778-4791.
26. Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood. 2002;100(1):230-237.
27. Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 2001;7(12):1339-1346.
28. Troy A, Davidson P, Atkinson C, Hart D. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol. 1998;160(1):214-219.
29. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res. 1998;4(3):585-593.
30. Coukos G, Benencia F, Buckanovich RJ, Conejo-Garcia JR. The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer. 2005;92(7):1182-1187.
31. Curiel TJ, Cheng P, Mottram P, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 2004;64(16):5535-5538.
32. Pellegatti P, Raffaghello L, Bianchi G, et al. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE. 2008;3(7):e2599.
33. la Sala A, Ferrari D, Corinti S, et al. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol. 2001;166(3):1611-1617.
34. Wilkin F, Duhant X, Bruyns C, et al. The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. J Immunol. 2001;166(12):7172-7177.
35. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol. 2004;164(5):769-779.
36. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, et al. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development. 2005;132(17):3923-3933.
37. Sternlicht MD, Sunnarborg SW. The ADAM17-amphiregulin-EGFR axis in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2008;13(2):181-194.
38. Novitskiy SV, Ryzhov S, Zaynagetdinov R, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008;112(5):1822-1831.
39. Ben Addi A, Lefort A, Hua X, et al. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. Eur J Immunol. 2008;38(6):1610-1620.
40. Cook PW, Pittelkow MR, Keeble WW, et al. Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res. 1992;52(11):3224-3227.
41. Ebert M, Yokoyama M, Kobrin MS, et al. Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res. 1994;54(15):3959-3962.
42. Kitadai Y, Yasui W, Yokozaki H, et al. Expression of amphiregulin, a novel gene of the epidermal growth factor family, in human gastric carcinomas. Jpn J Cancer Res. 1993;84(8):879-884.
43. Johansson CC, Yndestad A, Enserink JM, et al. The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3′,5′-monophosphate pathway in various cell types. Endocrinology. 2004;145(11):5177-5184.
44. Matsumoto K, Fukuda S, Nakamura Y, Saito H. Amphiregulin production by human eosinophils. Int Arch Allergy Immunol. 2009;149(1):39-44.
45. Ma L, de RA, Bertheau P, et al. Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions. J Pathol. 2001;194(4):413-419.
46. Orimo A, Tomioka Y, Shimizu Y, et al. Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression. Clin Cancer Res. 2001;7(10):3097-3105.
47. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456(7223):809-813.
48. White N, Knight GE, Butler PE, Burnstock G. An in vivo model of melanoma: treatment with ATP. Purinergic Signal. 2009;5(3):327-333.
49. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci. 2007;28(9):465-472.
50. Gu BJ, Wiley JS. Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood. 2006;107(12):4946-4953.